AI startups may solve one piece of the 150-problem drug discovery puzzle exceptionally well. However, they lack the scale to run enough experiments to prove their specific edge provides overall value, making them likely acquisition targets for Big Pharma's toolkits.

Instead of developing its own drugs, A-Alpha Bio strategically chose to provide data and services to the entire ecosystem. They believe they can have a broader impact on thousands of therapeutic programs by addressing the industry's data needs rather than focusing on a few internal assets.

Unlike traditional biotechs seeking pharma validation, Xaira's initial collaborations will be with tech companies for AI tools, lab automation, and compute. This reflects a strategy focused on building the core R&D engine first, seeking partners that accelerate platform development rather than provide capital.

Chai Discovery's partnership with Eli Lilly involves building a custom foundation model trained on Lilly's unique historical data. This signals a new collaboration model where AI firms act as specialized infrastructure builders, creating proprietary, data-moated AI for large pharmaceutical companies.

Chai Discovery's core philosophy is a direct application of "The Bitter Lesson" to biotech. They prioritize scaling compute, data, and simple models over creating complex, bespoke biological modules, betting that general-purpose learning methods will outperform human-engineered ones at scale.

Biotech business models have shifted from a high-risk, asset-centric approach to a platform-based model. Companies now focus on securing multiple early-stage partnerships, which is more capital-efficient and preserves optionality in a rapidly changing therapeutic landscape.

By choosing a partnership model over developing its own drugs, Chai Discovery subjects its AI to a higher bar. Its models must generalize across diverse targets for multiple partners like Pfizer and Eli Lilly, preventing them from creating bespoke solutions for a single problem. This business model forces technical rigor and scalability.

The relationship between AI startups and pharma is evolving rapidly. Previously, pharma engaged AI firms on a project-by-project, consulting-style basis. Now, as AI models for drug discovery become more robust, pharma giants are seeking to license them as enterprise-wide software suites for internal deployment, signaling a major inflection point in AI integration.

The field of AI for molecule design reached a critical inflection point in 2025. According to Chai Discovery's co-founder, models went from having sub-1% success rates to being actively deployed in the core discovery engines of major pharmaceutical companies like Eli Lilly and Pfizer within a single year.